SAFETY PROFILE COMPARABLE TO DAUNORUBICIN CYTARABINE (DA) THERAPY
IN PATIENTS WITH HIGH-RISK* ACUTE MYELOID LEUKAEMIA (AML)1

  • Adverse Events
  • Myelosuppression
  • Additional Safety Information

Comparable Overall Frequency and Severity of Grade 3–5 Adverse Events (AEs) vs. DA Therapy2-5

Grade 3-5 AEs in ≥5% of older adults with high-risk AML2-5

Refer to section 4.8 of the Summary of Product Characteristics for full safety information3

Five patients experienced AEs that led to treatment discontinuation:2

  • Vyxeos Liposomal: Cardiac failure, cardiomyopathy, and acute renal failure in one patient each
  • Conventional chemotherapy: Decreased ejection fraction in two patients

Prolonged Myelosuppression vs. DA Therapy3

Thrombocytopenia and neutropenia in older patients with high-risk AML3

Vyxeos Liposomal is associated with prolonged thrombocytopenia and neutropenia vs. DA therapy, so patients will require additional monitoring3

Hypersensitivity reactions3

Cardiotoxicity3

View the safety results of Vyxeos Liposomal in real-world cohorts

View

RELATED CONTENT

Superior overall survival
vs. DA therapy1

Discover more

Simplified infusion schedule
reduces the number of administration days
vs. DA therapy8

Discover more

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2100209 l September 2021